Eli Lilly has reported updates on its pipeline, including progress on an oral GLP-1 treatment, which may impact the company's growth prospects. The updates also touch on the company's efforts to expand beyond GLP-1 treatments, including investments in obesity and cancer therapies. The implications of these developments for Eli Lilly's investment narrative and valuation are being assessed.